A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker(University of Miami), Gareth J. Morgan(Hywel Dda University Health Board), Pieter Sonneveld(Erasmus MC Cancer Institute), Michael Bauer(University of Arkansas for Medical Sciences), Zhinuan Yu, Adam Rosenthal(Cancer Research And Biostatistics), Hermann Einsele(Universitätsklinikum Würzburg), Jesús F. San Miguel(Clinica Universidad de Navarra), Fadi Towfic, Sagar Lonial(Emory University), Brian G.M. Durie(Cedars-Sinai Medical Center), Dan Rozelle(Rancho BioSciences (United States)), Anjan Thakurta(University of Oxford), Kenneth C. Anderson(Dana-Farber Cancer Institute), Faith E. Davies(NYU Langone Health), Antje Hoering(Cancer Research And Biostatistics), Mehmet Samur(Dana-Farber Cancer Institute), Niccolò Bolli(University of Milan), Daniel Auclair(Multiple Myeloma Research Foundation), Raphaël Szalat(Boston University), Hartmut Goldschmidt(Heidelberg University), Mariateresa Fulciniti(Dana-Farber Cancer Institute), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), John C. Obenauer(Center for Cancer Research), Marc S. Raab(Unknown), Graham Jackson(Newcastle College), Matthew Trotter, Pingping Qu(Cancer Research And Biostatistics), Christopher P. Wardell(BMW (Germany)), Jonathan J. Keats(Translational Genomics Research Institute), Cody Ashby(Winthrop Rockefeller Foundation), Hongwei Wang(Nanjing Medical University), Nikhil Munshi(Johns Hopkins University), María Ortiz, Philippe Moreau(Centre National de la Recherche Scientifique), A. Keith Stewart(The University of Texas MD Anderson Cancer Center), Erin Flynt, Zhihong Yang, Konstantinos Mavrommatis(Bristol-Myers Squibb (Germany))
Leukemia
July 2, 2018
Cited by 452


Related Papers